# Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

> **NCT00650910** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 17 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** lapatinib
- **DRUG:** Digoxin

## Key facts

- **NCT ID:** NCT00650910
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-23
- **Primary completion:** 2009-07-10
- **Final completion:** 2009-07-10
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650910, "Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00650910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*